Addiction and Craving Reduction: Rewiring the Reward System With as much excitement for off-label use of GLP-1RAs, it appears the most exciting finding may be in the treatment of substance use disorders
According to a recent report by Morgan Stanley, the global market for obesity drugs is expected to increase 15-fold by 2030, driven by their expanding use beyond weight loss to address various obesity-related conditions
Many patients find it helpful to note the date, site, and any reactions in a medication diary or smartphone app
It pushed weight loss numbers into territory previously reserved for bariatric surgery discussions
How to Stop Bloating on GLP-1: Evidence-Based Strategies Bloating is one of the most commonly reported side effects of GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), and liraglutide (Saxenda, Victoza)
Evidence-based analysis of GH fragment vs GLP-1